Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) is now available.
Lee’s Pharmaceutical Holdings Limited has announced the death of Michele Dalla Libera, its Senior Director of Business Development, on 15 December 2025. Dalla Libera was instrumental in the group’s evolution after its 2002 listing, leading the in-licensing of key drug products from European partners and helping transform the company from a small biopharmaceutical player into a stronger organisation with a stable revenue foundation. The board expressed deep sorrow and extended condolences to his family, highlighting his leadership, professionalism and commitment to improving patients’ lives as enduring influences on the company’s mission and future development.
The most recent analyst rating on (HK:0950) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.
More about Lee’s Pharmaceutical Holdings Limited
Lee’s Pharmaceutical Holdings Limited is a Hong Kong–listed biopharmaceutical company that has developed a diversified portfolio of drug products, initially built through in-licensing arrangements with partners in Italy and other European markets, providing a solid revenue base for its operations.
Average Trading Volume: 2,192,157
Technical Sentiment Signal: Sell
Current Market Cap: HK$953.9M
See more insights into 0950 stock on TipRanks’ Stock Analysis page.